

Pfizer Limited

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

October 28, 2023

The Corporate Relationship Dept.	The Manager, Listing Dept.
BSE Limited	The National Stock Exchange of India Ltd.
1 st Floor, P.J.Towers	Exchange Plaza, 5 th Floor, Plot No. C/1,
Dalal Street, Fort	G Block Bandra-Kurla Complex, Bandra (E)
Mumbai – 400 001	Mumbai – 400 051
Scrip Code: 500680	Scrip Symbol: PFIZER

Dear Sirs,

Sub: Statement of Related Party Transactions for the half year ended September 30, 2023.

<u>Ref.:</u> <u>Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements)</u> <u>Regulations, 2015 ('Listing Regulations').</u>

Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended September 30, 2023.

The said disclosure is also available on the website of the Company i.e., www.pfizerltd.co.in

Request you to please take the above on record.

Thanking you,

Yours truly, For **Pfizer Limited**

Prajeet Nair Director – Corporate Services & Company Secretary

Pfizer Limited - Statement of Related Party Transactions pursuant to Regulation 23(9) of SEBI (LODR), 2015

				relates to loans, inter- corp							oorate de etails nee	ated party transactions - applicable only in case the related party transaction orate deposits, advances or investments made or given by the listed tails need to be disclosed only once, during the reporting period when such n.				
Sr. Details of the party Details of the counter party no listed entity entering into the transaction			Type of related party transaction	Value of the related Remarks on approval by party transaction as approved by the audit committee		transaction during the			In case any financial indebtedness Details of the loans, inter-corporate deposits, advances or invest is incurred to make or give loans, inter- corporate deposits, advances or investments			rporate deposits, advances or investments				
N	ame	P	PAN Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	ħ					-	Nature of Cost indebtedness (loan/ issuance of debt/ any other etc.)	Tenure	Nature (loan/ advance/ inter- corporate deposi investment	Rate (%)	: Tenure Secured/ Purpose for which the unsecured funds will be utilised the ultimate recipient of funds (end- usage)
. Pf	izer Lim	ited A	AAACP3334M Pfizer Service Company BVBA, Belgium	ZZZZZ9999Z	Fellow subsidiary	Purchase of Goods & Services	220.68	On arm's length basis and in Ordinary course of business		83.56	54.99			Not A	pplicable	
2 Pf	izer Lim	ited A	AAACP3334M Pfizer Healthcare India Private Limited	AABCO2190F	Fellow subsidiary	Service Income	1.96	On arm's length basis and in Ordinary course of business		-4.05	-2.48			Not A	pplicable	
Pf	izer Lim	ited A	AAACP3334M Pfizer Products India Private Limited	AADCP8985B	Fellow subsidiary	Service Income	14.12	On arm's length basis and in Ordinary course of business		-9.58	-14.31			Not A	pplicable	
4 Pf	izer Lim	ited A	AAACP3334M Pfizer Export B.V.	ZZZZZ9999Z	Fellow subsidiary	Service Income	0.16	On arm's length basis and in Ordinary course of business	0.16	0	-0.15			Not A	pplicable	
5 Pf	izer Lim	ited A	AAACP3334M Pfizer Worldwide Services Company	ZZZZ29999Z	Fellow subsidiary	Service Income	35.65	On arm's length basis and in Ordinary course of business	35.65	-20.19	-26.41			Not A	pplicable	
6 Pf	izer Lim	ited A	AAACP3334M Pfizer Products India Private Limited	AADCP8985B	Fellow subsidiary	Recovery of expense	0.19	On arm's length basis and in Ordinary course of business		0	0			Not A	pplicable	
7 Pf	izer Lim	ited A	AAACP3334M Pfizer Healthcare India Private Limited	AABCO2190F	Fellow subsidiary	Recovery of expense	0.45	On arm's length basis and in Ordinary course of business	0.45	0	0			Not A	pplicable	
8 Pf	izer Lim	ited A	AAACP3334M Pfizer East India B. V	AAGCP7832A	Companies holding significant influence	Payment of Dividend	72.75	On arm's length basis and in Ordinary course of business	72.75	0	0			Not A	pplicable	
9 Pf	izer Lim	nited A	AAACP3334M Wyeth LLC	AADCA9739J	Companies holding significant influence	Payment of Dividend	22.47	On arm's length basis and in Ordinary course of business		0	0			Not A	pplicable	
10 Pf	izer Lim	ited A	AAACP3334M Wyeth Holdings LLC	AAACA5142N	Companies holding significant influence	Payment of Dividend	6.52	On arm's length basis and in Ordinary course of business		0	0			Not A	pplicable	
11 Pf	izer Lim	ited A	AAACP3334M Warner Lambert Company LLC	AAACW4997K	Companies holding significant influence	Payment of Dividend	4.75	On arm's length basis and in Ordinary course of business		0	0			Not A	pplicable	
12 Pf	izer Lim	ited A	AAACP3334M Parke,Davis & Company LLC	AADCP1134C	Companies holding significant influence	Payment of Dividend	3.82	On arm's length basis and in Ordinary course of business		0	0			Not A	pplicable	
13 Pf	izer Lim	ited A	AAACP3334M John Wyeth & Brother Limited	AAACJ1732F	Companies holding significant influence	Payment of Dividend	3.53	On arm's length basis and in Ordinary course of business		0	0			Not A	pplicable	
14 Pf	izer Lim	ited A	AAACP3334M Pharmacia LLC	AAECP7868A	Companies holding significant influence	Payment of Dividend	3.14	On arm's length basis and in Ordinary course of business		0	0			Not A	pplicable	
15 Pf	izer Lim	ited A	AAACP3334M Ms. Meenakshi Nevatia	ABSPN7808E	Key Managerial Personnel	Remuneration	3.86	On arm's length basis and in Ordinary course of business		0	0			Not A	pplicable	
16 Pf	izer Lim	ited A	AAACP3334M Mr. Milind Patil	AAEPP3949B	Key Managerial Personnel	Remuneration	1.92	On arm's length basis and in Ordinary course of business		0	0			Not A	pplicable	

17 Pfizer Limited	AAACP3334M Mr. Samir Kazi*	AJSPK0243Q Key Managerial Personnel	Remuneration	1.39	On arm's length basis and in Ordinary course of business	1.39	0	0	Not Applicable
18 Pfizer Limited	AAACP3334M Mr. Prajeet Nair	AADPN9155G Key Managerial Personnel	Remuneration	0.52	On arm's length basis and in Ordinary course of business	0.52	0	0	Not Applicable
19 Pfizer Limited	AAACP3334M Mr. Pradip Shah	AAEPS0592F Independent Director	Sitting Fees	0.04	On arm's length basis and in Ordinary course of business	0.04	0	0	Not Applicable
20 Pfizer Limited	AAACP3334M Mr. Uday Khanna	AFEPK7061E Independent Director	Sitting Fees	0.03	On arm's length basis and in Ordinary course of business	0.03	0	0	Not Applicable
21 Pfizer Limited	AAACP3334M Mr. Sunil Lalbhai	AAFPL0691R Independent Director	Sitting Fees	0.03	On arm's length basis and in Ordinary course of business	0.03	0	0	Not Applicable
22 Pfizer Limited	AAACP3334M Ms. Meena Ganesh	ABPPG1456L Independent Director	Sitting Fees	0.02	On arm's length basis and in Ordinary course of business	0.02	0	0	Not Applicable

* Mr. Samir Kazi ceased to be the Executive Director - Legal of the Company effective September 12, 2023 close of business